Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.69 |
| ▸ | TGM2 | P21980 | 1/20 | 0.64 |
| ▸ | IMPDH2 | P12268 | 7/20 | 0.64 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.64 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.62 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.62 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.60 |
| ▸ | CA5A | P35218 | 1/20 | 0.59 |
| ▸ | KRAS | P01116 | 3/20 | 0.58 |
| ▸ | HINT1 | P49773 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17586739 | 1.00 | NT5E (0.69) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| SCHEMBL4308355 | 0.93 | TGM2 (0.70) | NT5ETGM2IMPDH2IMPDH1FUT5 | |
| SCHEMBL29355115 | 0.93 | TGM2 (0.65) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| SCHEMBL2826595 | 0.93 | NT5E (0.64) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| SCHEMBL2315645 | 0.93 | NT5E (0.69) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| SCHEMBL1533806 | 0.93 | NT5E (0.64) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| SCHEMBL94114 | 0.93 | NT5E (0.64) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| SCHEMBL3178906 | 0.93 | NT5E (0.64) | NT5ETGM2IMPDH2IMPDH1TAS1R3 | |
| SCHEMBL1622482 | 0.92 | TGM2 (0.69) | NT5ETGM2FUT5KRAS | |
| SCHEMBL4997841 | 0.92 | NT5E (0.77) | NT5ETGM2IMPDH2IMPDH1TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024239431-A1 | METHOD FOR PHOSPHORYLATION OF NUCLEIC ACID AT 3' END AND LIBRARY CONSTRUCTION | 深圳华大智造科技股份有限公司 | 2024-11-28 | — | — | WO | claimed |
| EP-2911699-B1 | MODIFIED ANTIBODY, ANTIBODY-CONJUGATE AND PROCESS FOR THE PREPARATION THEREOF | SYNAFFIX BV (NL) | 2017-11-15 | — | — | EP | claimed |
| EP-1370548-B1 | P-THIENYLBENZYL-AMIDES SERVING AS AGONISTS OF ANGIOTENSIN-(1-7)-RECEPTORS, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-02-01 | — | — | EP | claimed |
| EP-1185527-B1 | 1-(P-THIENYLBENZYL)-IMIDAZOLES AS ANGIOTENSIN-(1-7) RECEPTOR AGONISTS, METHOD FOR THE PRODUCTION AND THE UTILIZATION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS | AVENTIS PHARMA GMBH (DE) | 2005-07-27 | — | — | EP | claimed |
| EP-0739630-B1 | Process for the simultaneous elimination of tumor necrosis factor alpha and bacterial lipopolysaccharides from whole blood and/or blood plasma | BRAUN MELSUNGEN AG (DE) | 2003-03-12 | — | — | EP | claimed |
| EP-0904110-B1 | NITRIC OXIDE DONORS CAPABLE OF REDUCING TOXICITY FROM DRUGS | NICOX SA (FR) | 2002-07-24 | — | — | EP | claimed |
| EP-0592989-B1 | Process of the selective and quantitative removal or preparation of tumor necrosis factor (TNF) and lipopolysaccharides (LPS) of aqueous solutions | BRAUN MELSUNGEN AG (DE) | 2002-05-08 | — | — | EP | claimed |
| EP-0739630-A2 | Process and apparatus for the simultaneous elimination of tumor necrosis factor aplha and bacterial lipopolysaccharides from whole blood and/or blood plasma | B. BRAUN MELSUNGEN AG (DE) | 1996-10-30 | — | — | EP | claimed |
| EP-0592989-A2 | Process of the selective and quantitative removal or preparation of tumor necrosis factor (TNF) and/or lipopolysaccharides (LPS) of aqueous solutions | B. BRAUN MELSUNGEN AG (DE) | 1994-04-20 | — | — | EP | claimed |
| EP-4532525-A1 | SYSTEMS, METHODS, AND COMPOSITIONS FOR RNA-GUIDED RNA-TARGETING CRISPR EFFECTORS WITH CAS7-11 VARIANTS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-04-09 | — | — | EP | disclosed |
| WO-2024239431-A1 | METHOD FOR PHOSPHORYLATION OF NUCLEIC ACID AT 3' END AND LIBRARY CONSTRUCTION | 深圳华大智造科技股份有限公司 | 2024-11-28 | — | — | WO | disclosed |
| WO-2023230498-A1 | SYSTEMS, METHODS, AND COMPOSITIONS FOR RNA-GUIDED RNA-TARGETING CRISPR EFFECTORS WITH CAS7-11 VARIANTS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20230087609-A1 | USE OF A SOLUBLE GUANYLATE CYCLASE (sGC) STIMULATOR OR OF A COMBINATION OF A sGC STIMULATOR AND AN sGC ACTIVATOR FOR CONDITIONS WHEREIN THE HEME GROUP OF sGC IS OXIDIZED OR WHEREIN sGC IS DEFICIENT IN HEME | UNIVERSITEIT MAASTRICHT (NL) | 2023-03-23 | — | — | US | disclosed |
| EP-4106741-A1 | USE OF A SOLUBLE GUANYLATE CYCLASE (SGC) STIMULATOR OR OF A COMBINATION OF A SGC STIMULATOR AND AN SGC ACTIVATOR FOR CONDITIONS WHEREIN THE HEME GROUP OF SGC IS OXIDIZED OR WHEREIN SGC IS DEFICIENT IN HEME | Universiteit Maastricht (NL) | 2022-12-28 | — | — | EP | disclosed |
| EP-0124352-A2 | Protected binding assay | TECHNICON INSTRUMENTS CORPORATION(a Delaware corporation) (US) | 1984-11-07 | — | — | EP | disclosed |
| US-4376165-A | Method of preparing an enzyme-labeled ligand for use in specific binding assays and the labeled conjugate produced thereby | MILES LABORATORIES, INC. (US) | 1983-03-08 | — | — | US | disclosed |
| US-4340668-A | Heme-labeled specific binding assay | MILES LABORATORIES, INC. (US) | 1982-07-20 | — | — | US | disclosed |
| US-4318982-A | FMN-Labeled specific binding assay | MILES LABORATORIES, INC. (US) | 1982-03-09 | — | — | US | disclosed |
| US-4318983-A | Fad-labeled specific binding assay monitored with apoglutathione reductase or apolipoamide dehydrogenase | MILES LABORATORIES, INC. (US) | 1982-03-09 | — | — | US | disclosed |
| US-4238565-A | Specific binding assay with a prosthetic group as a label component | MILES LABORATORIES, INC. (US) | 1980-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230087609-A1 | USE OF A SOLUBLE GUANYLATE CYCLASE (sGC) STIMULATOR OR OF A COMBINATION OF A sGC STIMULATOR AND AN sGC ACTIVATOR FOR CONDITIONS WHEREIN THE HEME GROUP OF sGC IS OXIDIZED OR WHEREIN sGC IS DEFICIENT IN HEME | GUCY1A1, GUCY1B1, GUCY1A2 | NT5E 805/4885TGM2 229/4885IMPDH2 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.